Tempest to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 08:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both...
Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update
August 15, 2022 08:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both...
Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference
July 07, 2022 08:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., July 07, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class¹ therapeutics that combine both...
Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance
June 09, 2022 08:00 ET
|
Tempest Therapeutics
TPST-1120 demonstrated monotherapy clinical benefit in patients with late-line advanced, poor-prognosis cancers where responses would be unexpectedRECIST responses observed with TPST-1120 combined...
Tempest to Present at the Jefferies Healthcare Conference
June 06, 2022 16:05 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both...
Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting
May 26, 2022 16:57 ET
|
Tempest Therapeutics
RECIST responses observed in IO-refractory patients and in IO-resistant indications 30% ORR in patients treated at the two highest TPST-1120 doses in combination with nivolumab (3/10); 20% ORR in...
Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights
May 13, 2022 08:00 ET
|
Tempest Therapeutics
Announced oral presentation of TPST-1120 Phase 1 monotherapy and combination therapy data at ASCOPresented positive preclinical data for TPST-1495 at AACRPresented positive preclinical data with...
Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting
April 27, 2022 10:01 ET
|
Tempest Therapeutics
Oral presentation for TPST-1120 completed Phase 1 trial resultsPoster presentation for TPST-1495 trial in progress SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Tempest...
Tempest Announces Private Placement Financing of $15 Million
April 27, 2022 08:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing novel therapeutics that combine both targeted...
Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting
April 08, 2022 13:00 ET
|
Tempest Therapeutics
Anti-tumor data from systemic novel TREX1 inhibitors designed to activate the STING pathway selectively in tumorsAdditional data further supporting and differentiating TPST-1495, a clinical-stage dual...